Epigral Limited
Epigral Limited, formerly known as Meghmani Finechem Ltd, incorporated in 2007, is a leading integrated manufacturer of chemicals in India. Epigral’s Dahej facility is a backward and forward integrated and automated complex with a well-planned infrastructure.
What Epigral files
- Investor Meet72
- Others48
- Important15
- Updates13
- Board Meeting9
- PPTs7
Epigral reported Q1FY27 PAT up 25% to ₹99 Cr, with revenue up 15% to ₹709 Cr. The board approved ₹600 Cr capex for a 1,25,000 TPA Epoxy Resin & Formulations plant and a Multi-Purpose Plant, targeting H2FY28 commissioning, leveraging internal raw materials.
Epigral Limited has incorporated a new wholly owned subsidiary, Epigral Advanced Materials Limited. This move aims to expand the company's chemical manufacturing business. The subsidiary starts with a paid-up capital of Rs. 0.01 Cr.
Epigral Limited's FY25-26 Sustainability Report shows strong ESG. Earned EcoVadis Silver Medal. Targets include carbon neutrality by 2030, 50% renewable energy by 2028 (38.14 MW capacity). Achieved zero fines, human rights, or corruption complaints.
Epigral is doubling CPVC (to 150 KTPA) and ECH (to 100 KTPA) capacity, commissioning Chlorotoluenes, and expanding renewable energy to 38.14 MW. Despite a challenging year with lower profitability (Revenue down 1% to ₹2,542 Cr, EBITDA down 20% to ₹567 Cr), the company proposed a ₹5.00 dividend.
Epigral reported record Q4FY26 revenue of ₹736 Cr, up 17% YoY, with PAT jumping 109% QoQ and EBITDA margins at 23%. A ₹5 per share dividend is proposed. Major CPVC and Epichlorohydrin capacity expansions are on track, targeting future growth.